首页 | 本学科首页   官方微博 | 高级检索  
     

ABCB5与V-ATPase在非小细胞肺癌中的表达及意义
引用本文:葛忠虎,程庆书,李小飞,王雪娇,张志培. ABCB5与V-ATPase在非小细胞肺癌中的表达及意义[J]. 临床肿瘤学杂志, 2013, 18(1): 15-19
作者姓名:葛忠虎  程庆书  李小飞  王雪娇  张志培
作者单位:710038 西安 第四军医大学唐都医院胸腔外科
摘    要:目的 检测ABCB5和空泡型ATP酶(V-ATPase)在非小细胞肺癌(NSCLC)中的表达,分析其在不同病理类型、分级、分期之间表达的差异及相关性。方法 采用免疫组化En Vinsion法检测ABCB5和V-ATPase在72例NSCLC组织中的表达情况,分析其在不同病理类型、病理分级和TNM分期NSCLC中的表达差异及两者表达的相关性。结果 ABCB5在肺鳞癌或腺癌中的阳性表达率分别为75.7%和80.0%,差异有统计学意义(P=0.012);ABCB5表达在鳞癌或腺癌不同病理分级之间差异显著(P=0.030,P=0.036),但在不同TNM分期之间的表达无显著差异(P=0.179,P=0.844)。V-ATPase在鳞癌或腺癌中的阳性表达率分别为64.9%和82.9%,差异有统计学意义(P=0.000);V-ATPase在鳞癌或腺癌不同病理分级之间差异显著(P=0.040,P=0.010),但在不同TNM分期之间的表达无显著差异(P=0.918,P=0.545)。ABCB5和V-ATPase蛋白表达在NSCLC、腺癌或鳞癌中均呈正相关(P<0.05)。结论 ABCB5和V-ATPase在NSCLC中高表达,其与病理分级有关;两者在NSCLC中的表达存在正相关性,提示可能存在相互促进作用,这为研究ABCB5和V-ATPase在肿瘤中可能的耐药作用提供了依据。

关 键 词:非小细胞肺癌  ABCB5  V—ATPase  耐药
收稿时间:2012-10-18
修稿时间:2012-12-06

Expressions of ABCB5 and V-ATPase in non-small cell lung cancer and their significance
GE Zhonghu , CHENG Qingshu , LI Xiaofei , WANG Xuejiao , ZHANG Zhipei. Expressions of ABCB5 and V-ATPase in non-small cell lung cancer and their significance[J]. Chinese Clinical Oncology, 2013, 18(1): 15-19
Authors:GE Zhonghu    CHENG Qingshu    LI Xiaofei    WANG Xuejiao    ZHANG Zhipei
Affiliation:Department of Thoracic Surgery, Tangdu Hospital, the Fourth Military Medical University, Xi'an 710038, China
Abstract:Objective To investigate the expressions of ABCB5 and vascuolar-H+-ATPase(V-ATPase) proteins in non-small cell lung cancer( NSCLC), and analyze the expression of ABCB5 and V-ATPase protein among different pathological types, pathological grades and TNM stages in tumor samples and their correlation. Methods The expressions of ABCB5 and V-ATPase in NSCLC were detected with EnVinsion immunohistochemistry method in tumor samples from 72 NSCLC patients and the expressions among different pathological types, pathological grades and TNM stages in tumor samples were analyzed by statistics. Results ABCB5 protein was highly expressed in lung squamous cell carcinoma and adenocarcinoma at 75.7% and 80. 0% with significant difference ( P =0. 012) ; and ABCB5 expression was significantly different in the pathological grades of lung squamous cell carcinoma and adenocarcinoma(P = 0. 030, P = O. 036) ; but there was no difference in the TNM stages ( P = 0. 179, P = 0. 844). V-ATPase protein was also highly expressed in lung squamous cell carcinoma and adenocarcinoma at 64. 9% and 82.9 % with significant difference (P = 0. 000). The expressions at different pathological grades of lung squamous cell carcinoma and adenocarcinoma was remarkable(P = 0. 040,P =0. 010) while there was no difference at the TNM stages(P =0. 918, P =0. 545). In addition, the correlation was found between the expression of ABCB5 and V-ATPase in total samples or in adenocarcinoma and squamons cell carcinoma by correlation test (P 〈 0. 05 ).Conclusion The ABCB5 and V-ATPase proteins are highly expressed in NSCLC, and the level of expression is associated with the pathological grades. There is a positive correlation between the two proteins expressed in NSCLC. The expressions of ABCB5 and VATPase may provide an experimental evidence of muhidrug resistance for the future research.
Keywords:Non-small cell lung cancer  ABCB5  V-ATPase  Drug resistance
本文献已被 CNKI 维普 万方数据 等数据库收录!
点击此处可从《临床肿瘤学杂志》浏览原始摘要信息
点击此处可从《临床肿瘤学杂志》下载免费的PDF全文
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号